We provide trade advice to complement the prevailing
expert consensus on Concord Medical Serv. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. About
18.0% of the company shares are held by company insiders. Concord Medical Serv has price-to-book (P/B) ratio of 0.71. Some equities with similar Price to Book (P/B) outperform the market in the long run. The entity recorded a loss per share of
1.09. The firm last dividend was issued on the 23rd of December 2015. Concord Medical had
11384:10000 split on the 16th of January 2014.
The successful prediction of Concord Medical
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Concord Medical Services, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Concord Medical based on Concord Medical hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Concord Medical's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Concord Medical's related companies.
Watch out for price decline
Please consider monitoring Concord Medical on a daily basis if you are holding a position in it. Concord Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Concord Medical stock to be traded above the $1 level to remain listed. If Concord Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Concord expected Price
Concord Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Concord Medical technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Concord Medical trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Concord Medical Gross Profit
Concord Medical Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Concord Medical previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Concord Medical Gross Profit growth over the last 10 years. Please check Concord Medical's
gross profit and other
fundamental indicators for more details.
Is Concord Medical valued appropriately by the market?
Concord Medical Serv reported the last year's revenue of 34.94
M. Reported Net Loss for the year was (47.22
M) with loss before taxes, overhead, and interest of (15.83
M).
| 2017 | 2018 | 2019 | 2020 (projected) |
Interest Expense | 89.96 M | 46.23 M | 28.7 M | 37.79 M | Gross Profit | 563.96 M | 362.03 M | 412.56 M | 431.59 M |
Deferred Revenue Breakdown
Concord Medical Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Deferred Revenue may rise above about 1.4
M this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Concord Medical Deferred Revenue is relatively stable at the moment as compared to the past year. The company's current value of Deferred Revenue is estimated at 1.41 Million
| 2010 | 15.59 Million |
| 2011 | 13.12 Million |
| 2012 | 18.98 Million |
| 2013 | 15.67 Million |
| 2014 | 1.04 Million |
| 2015 | 1.52 Million |
| 2019 | 1.37 Million |
| 2020 | 1.41 Million |
Another 3 percent hike for Concord Medical
New skewness is at 1.46. As of the 4th of December, Concord Medical shows the
mean deviation of 3.07, and Risk Adjusted Performance of
(0.004447). Concord Medical Serv
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate data for nineteen
technical drivers for Concord Medical Services, which can be compared to its rivals. Please confirm
Concord Medical Serv jensen alpha, as well as the
relationship between the potential upside and
skewness to decide if Concord Medical Serv is priced correctly, providing market reflects its regular price of 2.4 per share. Please also double-check Concord Medical Services
total risk alpha, which is currently at
(0.66) to validate the company can sustain itself at a future point.
The Current Takeaway on Concord Medical Investment
While many of the other players under the medical care facilities industry are still a bit expensive, Concord Medical may offer a potential longer-term growth to stakeholders. On the whole, as of the 4th of December 2020, we believe that Concord Medical is currently
overvalued with
below average probability of distress in the next two years. Our ongoing 30 days 'Buy-vs-Sell' recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Concord Medical Services. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
